While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it ...

Merck (MRK) stock gains as BMO Capital Markets upgrades the company to Outperform citing strong portfolio moves before ...

Merck (MRK) stock is a buy as Q3 beats estimates, driven by Keytruda, pipeline growth, and strong technicals. Read here for more analysis.

European Space Agency (ESA) astronaut Thomas Pesquet removes the Protein Crystallization Facility hardware from an incubator ...

Bristol Myers Squibb (BMY), Gilead (GILD), and Merck (MRK), will be among the latest to announce agreements with the Trump administration to cut prices of certain prescription drugs in the U.S., ...

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...